The Friedreich’s Ataxia Research Alliance (FARA) funds and facilitates research to slow, stop, reverse, and cure Friedreich’s ataxia. FARA is a key resource for both FA families and …

Frataxin is a vital protein whose function is to help the mitochondria produce energy. It is also know that neurological cells in FA patients degenerate over time. Find out about our …

Friedreich’s ataxia (FA) is a genetic, progressive neuromuscular disease. People with FA experience issues with balance and coordination of movement that lead to life-altering loss of …

FARA is dedicated to supporting Friedreich’s ataxia research leading to treatments and cures for FA. Through funded grants, global initiatives, and partnerships with pharmaceutical …

Friedreich's ataxia is a debilitating, life-shortening, degenerative, neuro-muscular disorder. There are approximately 5,000 patients in the US and 15,000 globally. It is a single gene defect …

CureFA Foundation funds scientific projects and industry partnerships that leverage new technologies for the treatment and cure of Friedreich's Ataxia. Cure FA Foundation is …

The Friedreich’s Ataxia Research Alliance (FARA) is a national, public, 501 (c) (3), non-profit, tax-exempt organization dedicated to the pursuit of scientific research leading to treatments and a …

The Friedreich’s Ataxia Research Alliance (FARA) is a national, public, 501(c)(3), non-profit, organization dedicated to the pursuit of scientific research leading to treatments and a cure for …

FARA Europe was established to facilitate the creation of the new FA Global Clinical Consortium (FA GCC). FA GCC has been established to harmonize the natural history ecosystem allowing …

FARA Europe’s mission is to treat and cure Friedreich’s ataxia (FA) by marshaling and focusing European and global resources and relationships, by advancing treatments that will slow, stop …